PACIFIC SHUANGLIN BIO-PHARMACY CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.29 CNY | -1.61% |
|
-1.94% | +7.53% |
| Sales 2024 * | 2.95B 408M | Sales 2025 * | 3.34B 461M | Capitalization | 21.41B 2.96B |
|---|---|---|---|---|---|
| Net income 2024 * | 720M 99.44M | Net income 2025 * | 833M 115M | EV / Sales 2024 * | 7.25 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 6.41 x |
| P/E ratio 2024 * |
29.8
x | P/E ratio 2025 * |
25.8
x | Employees | 2,426 |
| Yield 2024 * |
0.34% | Yield 2025 * |
0.38% | Free-Float | 50.81% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.61% | ||
| 1 week | -1.94% | ||
| 1 month | +0.79% | ||
| 3 months | +24.90% | ||
| 6 months | +22.76% | ||
| Current year | +7.53% |
1 week
28.41
29.98
1 month
27.8830.64
Current year
21.2130.64
1 year
17.4931.25
3 years
16.2038.41
5 years
13.0950.31
10 years
8.9050.31
| Managers | Title | Age | Since |
|---|---|---|---|
Ye Hong Wang
DFI | Director of Finance/CFO | 33 | 21-03-25 |
Xiao Ying Huang
BRD | Director/Board Member | 50 | 23-10-24 |
Yu Lin Zhao
SEC | Corporate Secretary | 37 | 19-05-20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jun Yin
BRD | Director/Board Member | 69 | 23-10-24 |
Jin Gang Zhang
BRD | Director/Board Member | 61 | Dec. 10 |
Shao Lan Fu
CHM | Chairman | 82 | Dec. 10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.67% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 29.29 | -1.61% | 5,128,006 |
| 24-04-29 | 29.77 | -0.33% | 8,560,712 |
| 24-04-26 | 29.87 | +0.07% | 3,462,500 |
| 24-04-25 | 29.85 | +0.54% | 3,676,629 |
End-of-day quote Shenzhen S.E., April 29, 2024
More quotes
Pacific Shuanglin Bio pharmacy Co Ltd, formerly Southern Shuanglin Bio-pharmacy Co Ltd, formerly Zhenxing Biopharmaceutical & Chemical Co., Ltd., is a China-based company mainly engaged in the research, development, production and sales of blood products. The Company's main products are human albumin, intravenous immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin and rabies immunoglobulin. The Company mainly operates its business in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-05-21
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
29.29
CNY
Average target price
30
CNY
Spread / Average Target
+2.42%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +7.53% | 2.96B | |
| +1.45% | 40.51B | |
| -15.94% | 31.67B | |
| +52.66% | 24.62B | |
| -14.50% | 15.65B | |
| -14.38% | 12.07B | |
| -9.12% | 11.97B | |
| -42.56% | 11.61B | |
| +4.87% | 8.81B | |
| -4.33% | 8.5B |
- Stock Market
- Equities
- 000403 Stock
